利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

123 条记录 (耗时 0.043 秒)

    Use of 8-substituted-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives
    1.
    发明授权
    Use of 8-substituted-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives 失效
    8-取代-6,7,8,9-四氢嘧啶并[1,2-a]嘧啶-4-酮衍生物的用途

    公开(公告)号：US08093256B2

    公开(公告)日：2012-01-10

    申请号：US11764374

    申请日：2007-06-18

    申请人： Alistair Lochead ,  Mourad Saady ,  Franck Slowinski ,  Philippe Yaiche

    发明人： Alistair Lochead ,  Mourad Saady ,  Franck Slowinski ,  Philippe Yaiche

    IPC分类号： A61K31/519 ,  C07D487/04

    CPC分类号： A61K31/519 ,  C07D487/04

    摘要： The invention relates to use of substituted-pyrimidone derivatives represented by formula (I) or a salt thereof: wherein X, Y, R1, R2, R3, R4, R5, n, p and q are as defined herein. More specifically, the invention relates to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of GSK3β, such as Pick's disease among various other diseases as claimed herein.

    摘要翻译： 本发明涉及由式（I）表示的取代嘧啶酮衍生物或其盐的用途：其中X，Y，R 1，R 2，R 3，R 4，R 5，n，p和q如本文所定义。 更具体地，本发明涉及包含所述衍生物或其盐作为活性成分的药物，其用于预防和/或治疗GSK3＆bgr异常活性引起的疾病，例如各种其他疾病中的皮克病 如本文所要求的。

    ENANTIOMER OF TENATOPRAZOLE AND THE USE THEREOF IN THERAPY
    4.
    发明申请
    ENANTIOMER OF TENATOPRAZOLE AND THE USE THEREOF IN THERAPY 失效
    格拉唑的使用者及其在治疗中的应用

    公开(公告)号：US20090163539A1

    公开(公告)日：2009-06-25

    申请号：US12359410

    申请日：2009-01-26

    申请人： Setsuo YAMASHITA ,  Kengo EBINA

    发明人： Setsuo YAMASHITA ,  Kengo EBINA

    IPC分类号： C07D471/02 ,  A61K31/4745

    CPC分类号： C07D471/04

    摘要： This invention relates to optically active substances of tenatoprazole, (+) and (−) -5-methoxy-2-{(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl}-1H-imidazo[4,5-b]pyridine. The compound and pharmaceutical compositions thereof are useful for anti-ulcer agent.

    摘要翻译： 本发明涉及格拉唑（+）和（ - ） - 5-甲氧基-2 - {（4-甲氧基-3,5-二甲基-2-吡啶基）甲基]亚磺酰基} -1H-咪唑并[4 ，5-b]吡啶。 其化合物及其药物组合物可用于抗溃疡剂。

    Medical composition kit for treating lesioned abnormal tissue
    7.
    发明授权
    Medical composition kit for treating lesioned abnormal tissue 有权
    用于治疗病变异常组织的药物组合试剂盒

    公开(公告)号：US07381419B2

    公开(公告)日：2008-06-03

    申请号：US10297278

    申请日：2001-06-05

    申请人： Kinuko Oku ,  Takako Iwamoto ,  Takashi Ono

    发明人： Kinuko Oku ,  Takako Iwamoto ,  Takashi Ono

    IPC分类号： A61F9/02

    CPC分类号： A61K33/06 ,  A61K9/0031 ,  A61K31/167 ,  A61K31/245 ,  A61K31/70 ,  A61K31/165 ,  A61K2300/00

    摘要： Optimum compounding composition of a local injection preparation for treating rectal submucous lesioned abnormal tissue with local anesthetic is decided to provide a medical composition kit. In a composition kit for the treatment where respective containers are unsealed upon being used and respective contents are mixed to obtain a preparation for injection, a medical composition kit which is characterized in that respective single doses of a therapeutic preparation and local anesthetic are fractionally charged in containers, the said therapeutic preparation contains 1˜10% of a water-soluble aluminum compound and 0.01˜2% of tannic acid and the said local anesthetic contains 0.1˜1% of lidocaine hydrochloride or 0.5˜5% of procaine hydrochloride.

    摘要翻译： 决定用局部麻醉剂治疗直肠粘膜下损伤的异常组织的局部注射制剂的最佳配混组合物，以提供药物组合物试剂盒。 在用于治疗的组合物试剂盒中，其中各个容器在使用时是非密封的，并且各自的内容物被混合以获得注射制剂，该药物组合物试剂盒的特征在于将各自的单剂量的治疗制剂和局部麻醉剂分批装入 容器，所述治疗剂含有1〜10％的水溶性铝化合物和0.01〜2％的单宁酸，所述局部麻醉剂含有0.1〜1％的盐酸利多卡因或0.5〜5％的盐酸普鲁卡因。